TargetMol

PD-166866

Product Code:
 
TAR-T3492
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T3492-2mg2mg£98.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-1mL1 mL * 10 mM (in DMSO)£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-5mg5mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-10mg10mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-25mg25mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-50mg50mg£328.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3492-100mg100mg£454.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PD166866 is a selective FGFR tyrosine kinase inhibitor.
CAS:
192705-79-6
Formula:
C20H24N6O3
Molecular Weight:
396.451
Pathway:
Angiogenesis; Autophagy; Tyrosine Kinase/Adaptors
Purity:
0.9998
SMILES:
COc1cc(OC)cc(c1)-c1cc2cnc(N)nc2nc1NC(=O)NC(C)(C)C
Target:
FGFR; Autophagy

References

Chen Y, et al. Biochem Biophys Res Commun. 2016, 474(1):1-7. Panek RL, et al. J Pharmacol Exp Ther. 1998, 286(1):569-77. Risuleo G, et al. J Exp Clin Cancer Res. 2009, 28:151.